Serum Mac-2-binding protein (M2BPGi) as a marker of chronological liver fibrosis in biliary atresia patients with cirrhosis

Study demonstrates M2BPGi as a reliable serum biomarker for tracking liver fibrosis progression in pediatric biliary atresia patients with established cirrhosis. Eleven patients monitored over 22.6 months showed M2BPGi ratio correlates with clinical outcomes, with marked elevation (≥2.0) predicting decompensation to Child B status.